Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 2/20 | 0.46 |
| ▸ | GRM4 | Q14833 | 5/20 | 0.43 |
| ▸ | EGLN1 | Q9GZT9 | 4/20 | 0.37 |
| ▸ | ALKBH2 | Q6NS38 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 2/20 | 0.36 |
| ▸ | DRD4 | P21917 | 2/20 | 0.36 |
| ▸ | DRD3 | P35462 | 2/20 | 0.36 |
| ▸ | KDM5A | P29375 | 1/20 | 0.33 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | ATP4A | P20648 | 1/20 | 0.33 |
| ▸ | ATP4B | P51164 | 1/20 | 0.33 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24257678 | 0.88 | GRM4 (0.50) | GRM4KDM5ARIPK2 | |
| SCHEMBL24257536 | 0.83 | GRM4 (0.44) | GRM4DRD2DRD4DRD3KDM5A | |
| SCHEMBL24257533 | 0.82 | EGLN1 (0.46) | GRM5GRM4EGLN1ALKBH2KDM5A | |
| SCHEMBL24257581 | 0.81 | RET (0.38) | GRM4KDM5AATP4AATP4B | |
| SCHEMBL24257531 | 0.80 | GRM5 (0.52) | GRM5GRM4EGLN1ALKBH2DRD2 | |
| Nitrous Acid SCHEMBL29248972 | 0.80 | EGLN1 (0.44) | GRM5GRM4EGLN1ALKBH2KDM5A | |
| SCHEMBL24257579 | 0.79 | RET (0.40) | GRM4KDM5AADORA2AADORA2BADORA1 | |
| SCHEMBL24257687 | 0.79 | CYP11B1 (0.42) | ATP4AATP4B | |
| SCHEMBL24257723 | 0.79 | SQOR (0.38) | ATP4AATP4BTGFBR1 | |
| SCHEMBL30453144 | 0.79 | SQOR (0.38) | ATP4AATP4BTGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295110-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | AKEBIA THERAPEUTICS, INC. (US) | 2023-09-21 | — | — | US | disclosed |
| US-20230295110-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | AKEBIA THERAPEUTICS, INC. (US) | 2023-09-21 | — | — | US | disclosed |
| EP-4196466-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | Akebia Therapeutics Inc. (US) | 2023-06-21 | — | — | EP | disclosed |
| WO-2022036188-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | AKEBIA THERAPEUTICS, INC. (US) | 2022-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295110-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | HIF1AN, EGLN3, PHF20 | GRM5 1946/4885GRM4 3161/4885EGLN1 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.